A new study sheds light on the natural history and outcomes of UCB with isolated lymph node metastasis after resection. DLRS-based MLP was clinical useful in distinguishing non-muscle-invasive bladder cancer from muscle-invasive bladder cancer. A research team recently investigated the use of tubular damage biomarkers as prognostic markers for upper tract UC. MRE11 “has been identified as a candidate predictive biomarker," as higher levels are associated with more ... Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features. 1 of 4 will UTUC patients will have a variant histologic subtype such as squamous cell, micropapillary, or neuroendocrine. The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes. A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed. Out of 17 studies, adjuvant radiotherapy had no significant effect on UTUC, and radiotherapy had a negative impact on OS. Shilpa Gupta, MD, discusses the impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer. An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases. Enfortumab vedotin led to longer OS than chemotherapy in previously treated urothelial carcinoma. Most patients with locally advanced or metastatic urothelial carcinoma did not receive first-line systemic therapy. Petros Grivas, MD, PhD, Director of UW Medicine's GU Cancers Program, talks about the efficacy of sacituzumab govitecan. Shilpa Gupta, MD discusses maintenance therapy for bladder cancer, including the current standard of care and ongoing trials. Thomas Powles, MBBS, MRCP, MD gives an overview of highlights from The Uromigos: Live & Unplugged bladder cancer session. Matthew Galsky, MD gives insight on adjuvant nivolumab trials, including use in unselected patients and overall survival. Kala Sridhar talks about bladder-sparing treatments for urothelial carcinoma and how patient populations are shifting. Jonathan Rosenberg, MD talks about the development of enfortumab vedotin, including monotherapy info and combination data. At a 36-month follow-up, the EFS and OS rates were 74.4% and 83.8% in the ITT group, and 92% of patients underwent RC.